Furthermore, VEGF and basic Fibroblast Growth Factor (bFGF) secretion and cellular response are suppressed by thalidomide, thus antagonizing angiogenesis and altering the bone marrow stromal microenvironment in hematologic malignancies (Melchert and List, 2007; Shortt et al., 2013). Here, FGF2 is linked to hematologic disorder.